Eli Lilly and Company plans to invest $6.5 billion to build a manufacturing facility at Generation Park in Houston, Texas.

Pharmaceutical manufacturing is the industrial-scale process of producing medications through chemical synthesis, biotechnology, or extraction, ensuring both quality and regulatory compliance.

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, ...

Fluor is set to gain from U.S. pharma reshoring and rising sector investment, with strong fundamentals and value. Learn why ...

President Donald Trump announced Thursday that brand-name or patented pharmaceutical products will be subject to a 100% ...

The 100% tariff on imported drugs will pressure pharma companies to build manufacturing sites in the US or face significant ...

President Donald Trump says 100% tariffs on certain pharmaceuticals will take effect next week, but there are several ...

Francer is Lilly’s vice president, head of global regulatory policy and strategy. Cruz is Lilly’s senior vice president, ...

In a Truth Social post, Trump noted that the White House would place a 100% tariff on “any branded or patented” pharmaceutical product — unless a company was investing in manufacturing facilities in ...

With growing demand for advanced therapies, improved manufacturing processes are needed to provide flexibility and increase ...

Explore how AI in pharma manufacturing is being deployed with digital twins and predictive tools, which is reshaping CDMO timelines and sponsor expectations.

President Trump’s new pharmaceutical tariff policy throws another wrench into an already increasingly complex drug supply chain, with experts calling for more clarity and details into the ...